Effects of Angiotensin II Type 1 Receptor Antagonist, Losartan, on Ventilatory Response to Exercise and Neurohormonal Profiles in Patients with Chronic Heart Failure

Japanese Journal of Physiology

Volumn 54, Issue 1, 2004, Pages 15-21

  Kinugawa, Toru ^a   Kato, Masahiko ^a   Ogino, Kazuhide ^a   Osaki, Shuichi ^a   Igawa, Osamu ^a   Hisatome, Ichiro ^b   Shigemasa, Chiaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor antagonist; Cardiopulmonary exercise test; Heart failure; Losartan; Neurohormones; Ventilatory efficiency

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CARBON DIOXIDE; LOSARTAN; NEUROHORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EVALUATION; EXERCISE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE CONTRACTION; HUMAN; MALE; PHYSICAL ACTIVITY; RESPIRATORY FUNCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERVENTILATION; LOSARTAN; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PULMONARY VENTILATION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 1842631283     PISSN: 0021521X     EISSN: None     Source Type: Journal    
DOI: 10.2170/jjphysiol.54.15     Document Type: Article

References (35)

1. Awan NA and Mason DT: Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J 131: 177-185, 1996
2. Patel AR and Konstam MA: Recent advances in the treatment of heart failure. Circ J 66: 117-121, 2002
3. Cohn JN and Tognoni G (for the Valsartan Heart Failure Trial Investigators): A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001
4. Rigger GA, Bouzo H, Petr P, Munz J, Spacek R, Pethig H, von Behren V, George M, and Arens HJ (for the Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators): Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 100: 2224-2230, 1999
5. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari M-T, Thomas S, and Le Jemtel TH: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99: 990-992, 1999
6. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, and Kjekshus J: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26: 438-445, 1995
7. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, and DeKock M: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602-1609, 1993
8. 123I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure. Heart Vessels 17: 47-52, 2002
9. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto K, and Kinoshita M: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35: 714-721, 2000
10. Klinge R, Polis A, Dickstein K, and Hall C: Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. J Card Fail 3: 75-81, 1997
11. Metra M, Dei Cas L, Panina G, and Visioli O: Exercise hyperventilation chronic congestive heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol 70: 622-628, 1992
12. Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, Poole-Wilson PA, and Coats AJS: Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 29: 1585-1590, 1997
13. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, Sperfeld A, and Glaser S: Impairment of ventilatory efficiency in heart failure. Prognostic impact. Circulation 101: 2803-2809, 2000
14. Kinugawa T, Tomikura Y, Ogino K, Osaki S, Kato M, Igawa O, Hisatome I, and Shigemasa C: Relation between neurohormonal activation and enhanced ventilatory response to exercise in patients with chronic congestive heart failure. Am J Cardiol 89: 604-607, 2002
15. Miyagi K, Asanoi H, Ishizaka S, Kameyama T, Wada O, Seto H, and Sasayama S: Importance of total leg muscle mass for exercise intolerance in chronic heart failure. Jpn Heart J 35: 15-26, 1994
16. Kinugawa T, Ogino K, Noguchi N, Mori M, Miyakoda H, Hisatome I, and Shigemasa C: Sympathetic nervous response relative to the adenosine triphosphate supply-demand imbalance during exercise is augmented in patients with heart failure. Chest 114: 1295-1300, 1998
17. Whipp BJ: Ventilatory control during exercise in humans. Annu Rev Physiol 45: 393-413, 1983
18. Weber KT, Kinasewitz GT, Janicki JS, and Fishman AP: Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation 65: 1213-1223, 1982
19. Chua TP, Clark AL, Amadi AA, and Coats AJS: Relation between chemosensitivity and the increased ventilatory response to exercise in chronic congestive heart failure. J Am Coll Cardiol 27: 650-657, 1996
20. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, and Coats AJS: Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure. Effects of physical training. Circulation 93: 940-952, 1996
21. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, and Rucinska E (for the Losartan Hemodynamic Study Group): Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 91: 691-697, 1995
22. Omvik P, Gerdts E, Myking OL, and Lund-Johansen P: Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. Am Heart J 140: 624-630, 2000
23. Reindl I, Wernecke KD, Opitz C, Wensel R, Konig D, Dengler T, Schimke I, and Kleber FX: Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J 136: 778-785, 1998
24. Vescovo G, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, Ceconi C, and Ambrosio GB: Improved exercise tolerance after losartan and enalapril in heart failure. Correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 98: 1742-1749, 1998
25. Narang R, Swedberg K, and Cleland JG: What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 17: 120-134, 1996
26. Wilson JR, Rayos G, Yeoh TK, Gothard P, and Bak K: Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation 92: 47-53, 1995
27. Rodriguez-Garcia JL, Paule A, Dominguez J, Garcia-Escribano JR, and Vazquez M: Effects of angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure. Int J Cardiol 70: 293-301, 1999
28. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishio K, Yoshimasa T, and Nakao K: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96: 1280-1287, 1995
29. Richards MA, Crozier IG, Yandle TG, Espiner EA, Ikram H, and Nicholls MG: Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 69: 414-417, 1993
30. Yoshimura M, Yasue H, Okamura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, and Imura H: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87: 464-469, 1993
31. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, and Maisel A: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7: 21-29, 2001
32. Kinugawa T, Ogino K, Osaki S, Kato M, Igawa O, Hisatome I, Fujita M, and Shigemasa C: Prognostic significance of exercise plasma noradrenaline levels for cardiac death in patients with mild heart failure. Circ J 66: 261-266, 2002
33. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C-S, Kubo SH, Rudin-Toretsky E, and Yusuf S (for the SOLVD Investigators): Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724-1729, 1990
34. Jilma B, Krejcy K, Dimberger E, Eichler HG, Kapiotis S, Dorner GT, and Wagner OF: Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci 60: 1859-1866, 1997
35. Chua BH, Chua CC, Diglio CA, and Siu BB: Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1178: 201-206, 1993